Literature DB >> 26814171

How β3 -adrenoceptor-selective is mirabegron?

Martin C Michel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26814171      PMCID： PMC4728417          DOI： 10.1111/bph.13379

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  9 in total

1.  An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant.

Authors:  Stefan Tasler; Roland Baumgartner; Delphine Behr-Roussel; Stephanie Oger-Roussel; Diane Gorny; Francois Giuliano; Peter Ney
Journal:  Eur J Pharm Sci       Date:  2012-03-10       Impact factor: 4.384

2.  How β3 -adrenoceptor-selective is mirabegron?

Authors:  Martin C Michel
Journal:  Br J Pharmacol       Date:  2016-02       Impact factor: 8.739

3.  Do gene polymorphisms alone or in combination affect the function of human beta3-adrenoceptors?

Authors:  Wim Vrydag; Astrid E Alewijnse; Martin C Michel
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 4.  Selectivity of pharmacological tools: implications for use in cell physiology. A review in the theme: Cell signaling: proteins, pathways and mechanisms.

Authors:  Martin C Michel; Roland Seifert
Journal:  Am J Physiol Cell Physiol       Date:  2015-01-28       Impact factor: 4.249

5.  A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.

Authors:  Koji Ichihara; Naoya Masumori; Fumimasa Fukuta; Taiji Tsukamoto; Akihiko Iwasawa; Yoshinori Tanaka
Journal:  J Urol       Date:  2014-09-22       Impact factor: 7.450

6.  NSC23766, a widely used inhibitor of Rac1 activation, additionally acts as a competitive antagonist at muscarinic acetylcholine receptors.

Authors:  Magdolna Levay; Kurt Allen Krobert; Karola Wittig; Niels Voigt; Marcel Bermudez; Gerhard Wolber; Dobromir Dobrev; Finn Olav Levy; Thomas Wieland
Journal:  J Pharmacol Exp Ther       Date:  2013-07-25       Impact factor: 4.030

7.  Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.

Authors:  Walter Krauwinkel; Jan van Dijk; Marloes Schaddelee; Charlotte Eltink; John Meijer; Grégory Strabach; Sjoerd van Marle; Virginie Kerbusch; Marcel van Gelderen
Journal:  Clin Ther       Date:  2012-10       Impact factor: 3.393

8.  Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.

Authors:  Yasuhiko Igawa; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-21       Impact factor: 3.000

9.  Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.

Authors:  E C Alexandre; L R Kiguti; F B Calmasini; F H Silva; K P da Silva; R Ferreira; C A Ribeiro; F Z Mónica; A S Pupo; E Antunes
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739
  9 in total
  5 in total

1.  How β3 -adrenoceptor-selective is mirabegron?

Authors:  Martin C Michel
Journal:  Br J Pharmacol       Date:  2016-02       Impact factor: 8.739

Review 2.  β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions?

Authors:  Yasuhiko Igawa; Naoki Aizawa; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-05-03       Impact factor: 8.739

Review 3.  Mirabegron: potential off target effects and uses beyond the bladder.

Authors:  Nodi Dehvari; Edilson Dantas da Silva Junior; Tore Bengtsson; Dana Sabine Hutchinson
Journal:  Br J Pharmacol       Date:  2018-01-18       Impact factor: 8.739

4.  Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity.

Authors:  Alana E O'Mara; James W Johnson; Joyce D Linderman; Robert J Brychta; Suzanne McGehee; Laura A Fletcher; Yael A Fink; Devika Kapuria; Thomas M Cassimatis; Nathan Kelsey; Cheryl Cero; Zahraa Abdul Sater; Francesca Piccinini; Alison S Baskin; Brooks P Leitner; Hongyi Cai; Corina M Millo; William Dieckmann; Mary Walter; Norman B Javitt; Yaron Rotman; Peter J Walter; Marilyn Ader; Richard N Bergman; Peter Herscovitch; Kong Y Chen; Aaron M Cypess
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

Review 5.  On the Site and Mechanism of Action of β3-Adrenoceptor Agonists in the Bladder.

Authors:  Karl Erik Andersson
Journal:  Int Neurourol J       Date:  2017-03-24       Impact factor: 2.835
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.